CyberArk Case Studies Pharmaceutical Leader AstraZeneca Collaborates Securely
Edit This Case Study Record
CyberArk Logo

Pharmaceutical Leader AstraZeneca Collaborates Securely

CyberArk
Cybersecurity & Privacy - Identity & Authentication Management
Cybersecurity & Privacy - Security Compliance
Application Infrastructure & Middleware - Data Exchange & Integration
Pharmaceuticals
Healthcare & Hospitals
Business Operation
Product Research & Development
Remote Collaboration
System Integration
Software Design & Engineering Services
With $21.4 billion in annual sales, AstraZeneca is one of the top five pharmaceutical and health care services providers in the world. The pharmaceutical industry is highly competitive and regulated. In 2004, AstraZeneca invested $3.8 billion into new drug research and development, employing 11,900 people dedicated to this task. The company needed a secure and manageable way to collaborate internally and with external partners. Previously, AstraZeneca used an in-house secure collaborative application requiring a VPN client on each user’s system, which proved to be a high-management burden. Frequent help-desk calls and firewall adjustments were common issues. AstraZeneca needed a seamless, web-based solution with no setup overhead or firewall concerns.
Read More
AstraZeneca is a leading global pharmaceutical and healthcare services provider, headquartered in London, England. With an annual revenue of 21.4 billion Euros and over 84,000 employees, the company specializes in developing medicines for cancer, cardiovascular conditions, gastrointestinal disorders, the central nervous system, pain, and respiratory illnesses. AstraZeneca has a significant global presence, with 64,000 employees worldwide, including 12,000 in the United States. The company is heavily invested in research and development, spending $3.8 billion in 2004 alone, and employs 11,900 people dedicated to drug and treatment research. AstraZeneca's commitment to innovation and collaboration drives its need for secure and efficient information sharing solutions.
Read More
AstraZeneca chose CyberArk’s Sensitive Information Management solution after several internal pilots. The solution proved easy to deploy and maintain, requiring no code tweaks. CyberArk’s Vaulting Technology creates information 'safe havens' with layered security protection, including integrated firewall, authentication, access control, session and data encryption, content inspection, secure backup, and version control. End users need only a web browser to access the secure vaults, with information secured via HTTPS and specialized encryption. The solution supports various authentication methods, including public key infrastructure, RSA security, and Windows Domain authentication. Security managers can create specific access rights, limiting user and vault activity. AstraZeneca first deployed the solution within its drug development process, where it significantly sped up data and document exchange with business partners. The solution's version control mechanism prevents data corruption, proving extremely useful. AstraZeneca now uses the solution organization-wide, creating secure collaborative workgroups quickly and efficiently.
Read More
CyberArk’s Sensitive Information Management solution enabled AstraZeneca to exchange data and documents more quickly with business partners, significantly speeding up the drug development process.
The solution's powerful version-control mechanism protects against deliberate and unintentional data corruption, ensuring data integrity.
The ease of deployment and maintenance of CyberArk’s solution reduced the high-management burden previously experienced with the in-house application.
AstraZeneca invested $3.8 billion into new drug research and development in 2004.
The company employs 11,900 people dedicated to drug and treatment research and development.
It is estimated that it costs pharmaceutical companies $1 million for each day a drug is under development.
Download PDF Version
test test